Wolverine Asset Management LLC Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Wolverine Asset Management LLC bought a new position in Emergent BioSolutions Inc. (NYSE:EBS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 136,333 shares of the biopharmaceutical company’s stock, valued at approximately $1,303,000. Wolverine Asset Management LLC owned 0.25% of Emergent BioSolutions at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth $103,000. Hilltop Holdings Inc. boosted its stake in shares of Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 12,515 shares during the last quarter. FMR LLC boosted its stake in shares of Emergent BioSolutions by 12.6% during the 3rd quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,446 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth $141,000. Institutional investors own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on EBS. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS opened at $7.74 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market cap of $419.44 million, a P/E ratio of -1.89 and a beta of 1.62. The firm’s fifty day moving average is $9.66 and its two-hundred day moving average is $9.07. Emergent BioSolutions Inc. has a 52-week low of $1.82 and a 52-week high of $15.10.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.